<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887831</url>
  </required_header>
  <id_info>
    <org_study_id>G1T28-209</org_study_id>
    <nct_id>NCT04887831</nct_id>
  </id_info>
  <brief_title>Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab</brief_title>
  <acronym>PRESERVE3</acronym>
  <official_title>A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G1 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G1 Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and&#xD;
      efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib&#xD;
      administered with avelumab maintenance therapy compared with platinum-based chemotherapy&#xD;
      followed by avelumab maintenance therapy in patients receiving first-line treatment for&#xD;
      advanced/metastatic bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly assigned (1:1) to receive standard of care platinum-based&#xD;
      chemotherapy (with or without the addition of trilaciclib) administered intravenously (IV) in&#xD;
      21-day cycles followed by standard of care avelumab maintenance therapy (with or without the&#xD;
      addition of trilaciclib) administered IV in 14-day cycles.&#xD;
&#xD;
      Patients enrolled in the study will be eligible to receive 4-6 cycles of platinum-based&#xD;
      chemotherapy, and patients without progressive disease (PD) as per Response Evaluation&#xD;
      Criteria in Solid Tumors (RECIST) v1.1 guidelines (i.e., with an ongoing complete response&#xD;
      [CR], partial response [PR], or stable disease) after platinum-based chemotherapy will be&#xD;
      eligible to receive avelumab maintenance therapy until disease progression, unacceptable&#xD;
      toxicity, withdrawal of consent, Investigator decision, or the end of the trial, whichever&#xD;
      comes first.&#xD;
&#xD;
      Patients will be followed for survival approximately every 3 months after receiving the last&#xD;
      dose of study medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Random assignment (1:1) to one of two treatment arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>From date of randomization until date of documented radiologic disease progression per RECIST v1.1 or death due to any cause, whichever comes first (on average 7 months)</time_frame>
    <description>To evaluate the effect of trilaciclib on progression-free survival (PFS) when administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor Effects</measure>
    <time_frame>From date of randomization until date of documented radiologic disease progression per RECIST v1.1 or death due to any cause, whichever comes first (on average 7 months)</time_frame>
    <description>To assess objective response rates as measured by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor Effects</measure>
    <time_frame>From date of randomization until date of death due to any cause (on average 25 months)</time_frame>
    <description>To evaluate the effect of trilaciclib on overall survival (OS) when administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myeloprotective Effects</measure>
    <time_frame>Cycle 1 Day 1 (each cycle is 21 days) through treatment with platinum-based chemotherapy (up to 4 months)</time_frame>
    <description>To assess the effects of trilaciclib on the neutrophil lineage as measured by the occurrence of severe neutropenia during platinum-based chemotherapy treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Bladder Cancer</condition>
  <condition>Myelosuppression Adult</condition>
  <condition>Chemotherapy-induced Neutropenia</condition>
  <condition>Metastatic Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Platinum-based chemotherapy followed by avelumab maintenance therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) or Carboplatin (AUC 4.5) followed by Avelumab (800 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trilaciclib plus platinum-based chemotherapy followed by avelumab maintenance therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trilaciclib (240 mg/m2) + Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) or Carboplatin (AUC 4.5) followed by Trilaciclib (240 mg/m2) + Avelumab (800 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trilaciclib</intervention_name>
    <description>Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.</description>
    <arm_group_label>Trilaciclib plus platinum-based chemotherapy followed by avelumab maintenance therapy</arm_group_label>
    <other_name>Cosela</other_name>
    <other_name>G1T28</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle</description>
    <arm_group_label>Platinum-based chemotherapy followed by avelumab maintenance therapy</arm_group_label>
    <arm_group_label>Trilaciclib plus platinum-based chemotherapy followed by avelumab maintenance therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin administered IV on Day 1 of each 21-day cycle</description>
    <arm_group_label>Platinum-based chemotherapy followed by avelumab maintenance therapy</arm_group_label>
    <arm_group_label>Trilaciclib plus platinum-based chemotherapy followed by avelumab maintenance therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin administered IV on Day 1 of each 21-day cycle</description>
    <arm_group_label>Platinum-based chemotherapy followed by avelumab maintenance therapy</arm_group_label>
    <arm_group_label>Trilaciclib plus platinum-based chemotherapy followed by avelumab maintenance therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Avelumab will be dosed on Day 1 of each 14-day maintenance cycle</description>
    <arm_group_label>Platinum-based chemotherapy followed by avelumab maintenance therapy</arm_group_label>
    <arm_group_label>Trilaciclib plus platinum-based chemotherapy followed by avelumab maintenance therapy</arm_group_label>
    <other_name>Bavencio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Histologically documented, locally advanced (T4b, any N; or any T, N 2-3) or&#xD;
             metastatic urothelial carcinoma (M1, Stage IV)&#xD;
&#xD;
          3. Measurable disease as defined by RECIST v1.1&#xD;
&#xD;
          4. No prior systemic therapy in the inoperable, locally advanced, or metastatic setting&#xD;
             including chemotherapy, immune checkpoint inhibitor therapy, targeted therapy, or&#xD;
             investigational agents&#xD;
&#xD;
          5. Archival tumor tissue must be available or a fresh biopsy must be obtained, unless&#xD;
             approved by the Medical Monitor&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          7. Adequate organ function as demonstrated by normal laboratory values&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with IL-2, IFN-α, or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137&#xD;
             or CD137 agonists, or cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody&#xD;
             (including ipilimumab), or any other therapeutic antibody or drug specifically&#xD;
             targeting T cell co-stimulation or immune checkpoint pathways in any setting&#xD;
&#xD;
          2. Malignancies other than urothelial carcinoma within 3 years prior to randomization,&#xD;
             except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in&#xD;
             situ of the breast or of the cervix, or low-grade (Gleason ≤6) prostate cancer on&#xD;
             surveillance without any plans for treatment intervention (e.g., surgery, radiation,&#xD;
             or castration)&#xD;
&#xD;
          3. Presence of central nervous system (CNS) metastases/leptomeningeal disease requiring&#xD;
             immediate treatment with radiation therapy or steroids.&#xD;
&#xD;
          4. QTcF interval &gt; 480 msec. For patients with ventricular pacemakers, QTcF &gt; 500 msec&#xD;
&#xD;
          5. Known hypersensitivity or allergy to avelumab, gemcitabine, cisplatin or carboplatin&#xD;
&#xD;
          6. Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥3), any&#xD;
             history of anaphylaxis, or uncontrolled asthma&#xD;
&#xD;
          7. Prior hematopoietic stem cell or bone marrow transplantation, or solid organ&#xD;
             transplantation&#xD;
&#xD;
          8. Pregnant or lactating women&#xD;
&#xD;
          9. Active autoimmune disease that might deteriorate when receiving an immunostimulatory&#xD;
             agent&#xD;
&#xD;
         10. Current use of immunosuppressive medication, EXCEPT for the following:&#xD;
&#xD;
               1. Intranasal, inhaled, topical steroids, or local steroid injection (e.g.,&#xD;
                  intra-articular injection)&#xD;
&#xD;
               2. Systemic corticosteroids at physiological doses ≤10 mg/day of prednisone or&#xD;
                  equivalent&#xD;
&#xD;
               3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
                  premedication)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Contact</last_name>
    <role>Study Director</role>
    <affiliation>G1 Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>G1 Therapeutics, Inc. Clinical Contact</last_name>
    <phone>919-213-9835</phone>
    <email>clinicalinfo@g1therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Bettino</last_name>
      <phone>562-693-4477</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Eddie Thara, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne Boynton</last_name>
      <phone>303-730-4700</phone>
      <email>lynne.boynton@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Manojkumar Bupathi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Chu</last_name>
      <phone>239-236-5680</phone>
      <email>amy.chu@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Ann Guancial, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodlands Medical Specialists</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Bellamy</last_name>
      <phone>850-696-4000</phone>
      <phone_ext>4423</phone_ext>
      <email>lbellamy@woodlandsmed.com</email>
    </contact>
    <investigator>
      <last_name>Rami Owera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists , North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BJ Conklin</last_name>
      <phone>727-216-1143</phone>
      <email>bconklin@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Harry and Jeanette Weinberg Cancer Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Avergas</last_name>
      <phone>443-777-8876</phone>
      <email>amy.m.avergas@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Kevin Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Saavedra</last_name>
      <phone>410-964-2212</phone>
      <phone_ext>1151</phone_ext>
      <email>teresa.saavedra@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Vinni Juneja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josephine Faruol</last_name>
      <phone>518-489-0044</phone>
      <email>Josephine.Faruol@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Ambri Cicchineli</last_name>
      <email>Ambri.Cicchinelli@USONCOLOGY.COM</email>
    </contact_backup>
    <investigator>
      <last_name>Rahul Ravilla, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rikin Gandhi</last_name>
      <phone>718-862-8840</phone>
      <phone_ext>451</phone_ext>
      <email>rigandhi@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Celeste Broyles</last_name>
      <phone>516-470-6924</phone>
      <email>cbroyles@brany.com</email>
    </contact_backup>
    <investigator>
      <last_name>Benjamin Gartrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deonna Coleman</last_name>
      <phone>716-529-6470</phone>
      <email>DColeman1@KaleidaHealth.org</email>
    </contact>
    <investigator>
      <last_name>Roberto Pili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Tigard</city>
        <state>Oregon</state>
        <zip>46241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Kern</last_name>
      <phone>360-597-1316</phone>
      <email>Julian.Kern@compassoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ian Schnadig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Arellano</last_name>
      <phone>512-427-9400</phone>
      <email>monica.arellano@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Yorio, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Cancer Associates PA</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liana Maldanado</last_name>
      <phone>956-688-9042</phone>
      <email>liana.maldonado@elligodirect.com</email>
    </contact>
    <investigator>
      <last_name>Todd Shenkenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Maxfield</last_name>
      <phone>903-757-2122</phone>
      <email>Shelly.Maxfield@USOncology.com</email>
    </contact>
    <investigator>
      <last_name>Lijo John, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, PS (dba Summit Cancer Centers)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Chaudhry</last_name>
      <phone>509-462-2273</phone>
    </contact>
    <contact_backup>
      <email>monika.chaudhry@aoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Arvind Chaudhry, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Országos Onkológiai Intézet</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramona Kucsera</last_name>
      <phone>+36 20 999 7483</phone>
      <email>ramona.kucsera@coordination.hu</email>
    </contact>
    <contact_backup>
      <last_name>Alexa Stallenberger</last_name>
      <phone>+36 20-290-9561</phone>
      <email>alexa.stallenberger@coordination.hu</email>
    </contact_backup>
    <investigator>
      <last_name>Lajos Geczi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona - Servicio de Oncología Médica</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Oliva</last_name>
      <phone>34 932275400</phone>
      <phone_ext>1491</phone_ext>
      <email>laoliva@clinic.cat</email>
    </contact>
    <contact_backup>
      <last_name>Martín Álvarez</last_name>
      <phone>34 932275400</phone>
      <phone_ext>1492</phone_ext>
      <email>malvarezv@clinic.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Oscar Reig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trilaciclib dihydrochloride/Cosela</keyword>
  <keyword>Metastatic Urothelial Carcinoma</keyword>
  <keyword>Cyclin-dependent kinase 4/6 inhibitor</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Chemotherapy-induced myelosuppression</keyword>
  <keyword>Myeloprotective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

